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Mesenchymal stem cell (MSC) transplantation is used for treatment of many diseases. The paracrine
role of MSCs in tissue regeneration is attracting particular attention. We investigate the role of MSC
exosomes in skeletal muscle regeneration. MSC exosomes promote myogenesis and angiogenesis
in vitro, and muscle regeneration in an in vivo model of muscle injury. Although MSC exosomes
had low concentrations of muscle-repair-related cytokines, a number of repair-related miRNAs
were identiﬁed. This study suggests that the MSC-derived exosomes promote muscle regeneration
by enhancing myogenesis and angiogenesis, which is at least in part mediated by miRNAs such as
miR-494.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mesenchymal stem cells (MSCs) differentiate into many cell
types, including osteoblasts, chondrocytes, adipocytes, and myo-
blasts [1]. There is considerable interest in the clinical application
of MSCs for the treatment of many diseases. However, several stud-
ies have reported transplanted MSCs show poor engraftment efﬁ-
ciency and have not always shown tissue-speciﬁc differentiation
[1–3]. Although the transplantation of MSCs promoted the
regeneration of skeletal muscle in a rat injury model, the cells
did not differentiate into skeletal myoﬁbers [4]. Our previous study
indicated MSCs contribute to the regeneration of skeletal muscleby mechanisms other than myogenic differentiation [4].
Therefore, the paracrine role of MSCs is attracting attention to
explain their effect on tissue regeneration. Many reports have
demonstrated that the paracrine activity of MSCs has a therapeutic
effect on a variety of diseases, tissue injury in myocardium [5], kid-
ney [6], liver [7], and lung [8].
Recently, extracellular vesicles, including exosomes, have
attracted attention as new players in cell-to-cell communication.
Exosomes are vesicle of the multivesicular body, a complex intra-
cellular organelle involved in endocytosis. The diameter of exo-
somes is typically 30–200 nm. After multivesicular bodies fuse
with the plasma membrane, exosomes are released from the cells
into the extracellular environment. Exosomes contain messenger
RNA (mRNA) and microRNA (miRNA) as well as proteins, and the
functional RNAs can be transferred from one cell to another by
the exosome [9,10]. The properties of exosomes reﬂect the special-
ized properties of their original cells and the environment. In fact,
recent studies have shown that microvesicles derived from MSCs
have regenerative functions in several tissues, including kidney,
heart, nervous tissues, liver, and lung [11–20]. We hypothesized
that exosomes from MSCs exert a novel paracrine effect on skeletal
muscle repair during MSC transplantation, in addition to their
secretion of cytokines, chemokines, or growth factors.
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2.1. Culture of human MSCs and synovial ﬁbroblasts
Four independent human bone-marrow-derived MSCs were
obtained from Lonza (Basel, Switzerland) and cultured in MSC
growth medium (Lonza). MSCs at passage 4–5 were used in the
experiments. Human synovial ﬁbroblasts (SFB) were isolated and
cultured as described previously [21].
2.2. Preparation of conditioned medium and isolation of exosomes
MSCs were seeded at 1.0  105/well in a six-well plate with
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Life Technologies,
USA) containing 10% fetal bovine serum (FBS; Life Technologies)
and 1% antibiotic–antimycotic solution (Nacalai Tesque, Japan).
The cells were washed with serum-free DMEM and cultured with
2 ml/well serum-freeDMEMfor 48 hat 37 Cunder 5%CO2. The con-
ditionedmedia (MSC-CM)were collectedand centrifuged for 15 min
at 2380g, and then further ultracentrifuged for 70 min at
110000g (Optima TL ultracentrifuge, Beckman Coulter, USA). The
supernatants were collected, and were concentrated using Amicon
Ultra-2 centrifugalﬁlters (Millipore,USA) as exosome-depleted con-
ditioned media (MSC-CM (exo)). To isolate the exosomes (MSC-
exosomes), the pellets were washed in Phosphate-buffered saline
(PBS) and a second ultracentrifugation was performed for 70 min
at 110000g. The exosomes isolated from the same volumes of cul-
ture medium from the same numbers of cells were resuspended in
PBS or DMEM for use as fresh preparation.
2.3. Immunoblotting of exosome markers
The exosome marker proteins from the cells, the exosomes, and
the MSC-CM (exo) were detected by immunoblotting. Anti-ﬂotil-
lin-1 antibody (610820; diluted 1:500; BD Biosciences, USA), pur-
iﬁed mouse anti-human CD9 antibody (diluted 1:200; BD
Bioscience), and anti-CD81 antibody (sc-7637; diluted 1:200;
Santa Cruz Biotechnology, USA) were used as primary antibodies.
Horseradish peroxidase (HRP)-conjugated IgG antibody (sc-2005,
sc-2030; Santa Cruz Biotechnology) was used as the secondary
antibody.Fig. 1. Exosome isolation from mesenchymal-stem-cell-derived conditioned medium
supernatant for exosomal surface proteins: CD9, CD81, and ﬂotillin-1. (B) The size d
Abbreviations: hMSC, human mesenchymal stem cell.2.4. Exosome size analysis
Exosomes isolated by ultracentrifugation were resuspended in
100 mM KCl and 40 mMHEPES. The sizes and numbers of MSC par-
ticles were measured on an Izon qNano system with tunable resis-
tive pulse sensor (TRPS) technology (Izon Science, New Zealand), as
previously reported [22].
2.5. Culture of C2C12 cells for myogenesis
The mouse C2C12 myoblast cell line (American Type Culture
Collection) was cultured in DMEM containing 10% FBS. The
C2C12 cells were seeded at 2.0  104/well in a 24-well plate. To
examine the effects of exosomes on myogenic differentiation, the
medium was changed to DMEM, MSC-conditioned medium
(MSC-CM), MSC-exosome suspension in DMEM (MSC-exosome),
or exosome-depleted MSC-conditioned medium (MSC-CM (exo))
containing 2% horse serum (Life Technologies). The cells were incu-
bated at 37 C under 5% CO2 for 4 days.
2.6. Quantitative real-time PCR
Total RNA was extracted from them using TRIzol Reagent
(Invitrogen). Complementary DNA (cDNA) was synthesized using
1 lg of total RNA with the SuperScript VILO cDNA Synthesis Kit
(Invitrogen). A real-time PCR assay was performed using TaqMan
Gene Expression Assay probes (Life Technologies) to amplify the
MyoD gene (Myod1; Mm00440387_m1) and Myogenin gene
(Myog; Mm00446194_m1). The glyceraldehyde-phosphate dehy-
drogenase gene (Gapdh; Mm99999915_g1) was used as the inter-
nal control to normalize the sample differences. The DDCt method
was used to analyze the real-time PCR data.
2.7. Immunocytochemical analysis of the myosin heavy chain
The C2C12 cells were ﬁxed with 4% paraformaldehyde after
4 days in differentiation medium. The cells were incubated over-
night at 4 C with primary mouse anti-F59 (myosin heavy chain)
antibody (Hybridoma Bank, USA). They were incubated with sec-
ondary antibody, Alexa-Fluor-568-conjugated goat anti-mouse
IgG antibody (Molecular Probes; Invitrogen) for 1 h at room tem-
perature. 40,6,-Diamidino-2-phenylindole (DAPI; Dojindo
Laboratories, Japan) solution was applied for 5 min to stain theby ultracentrifugation. (A) Immunoblotting of the ultracentrifugation pellet and
istribution of the particles in the pellet was measured with the qNano system.
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at 200 magniﬁcation. The total numbers of nuclei were counted
to evaluate cell proliferation, and the fusion index (ratio of the
nuclei in myotubes to all nuclei) was calculated to evaluate myo-
genic differentiation.
2.8. Culture of HUVECs and migration assay
Human umbilical-vein endothelial cells (HUVECs) were pur-
chased from Lonza and were maintained in EBM-2 (Lonza) supple-
mented with 10% FBS and growth factors (BulletKit, Lonza).
HUVECs suspended in 500 ll of serum-free DMEM were seeded
at 2  104/well to the 24-well upper chamber of a cell culture
insert with an 8.0 lm pore polyethylene terephthalate track-
etched membrane (BD Falcon Cell Culture inserts; BD
Biosciences, Canada). The chambers were placed in 24-well plates.Fig. 2. Effects of MSC-exosomes on the differentiation of C2C12 cells. (A) Immunocytoch
Myotubes are stained red and nuclei are stained blue. Original magniﬁcation, 200. (B) T
differentiation of C2C12 cells. (C) Real-time PCR analysis of the marker genes of myo
differentiation. All data were calculated as means ± S.E. (n = 5). Statistical analysis was
Abbreviations: control, DMEM; MSC-CM, mesenchymal-stem-cell-derived conditione
conditioned medium; MSC-exosomes, mesenchymal-stem-cell-derived exosome suspenDMEM, MSC-CM, MSC-exosomes, or MSC-CM (exo) was added to
the bottom well of the multiwall insert assembly in 750 ll of
serum-free medium. After incubation for 4 h, the lower side of
the ﬁlter was ﬁxed with 4% paraformaldehyde. The migrated cells
were quantiﬁed as the number of cell nuclei stained with DAPI.
2.9. Tube formation assay
An angiogenesis assay kit (Kurabo, Japan) was used for the tube
formation assay, according to the manufacturer’s instructions.
HUVECs were cultured with DMEM, MSC-CM, MSC-exosomes, or
MSC-CM (exo). After 4 days, the medium was replaced with the
same conditioned medium. After 8 days, the cells were ﬁxed with
ethanol and the newly formed tubes were visualized with a tubule
staining kit (Kurabo). Micrographs were taken at 40 magniﬁca-
tion in all ﬁelds per well and image fusion was performed. The totalemical analysis of myosin heavy chain 4 days after the induction of differentiation.
otal nuclei numbers indicate myoblast proliferation. The fusion index indicates the
genesis, Myod1 and Myog, in C2C12 cells 1, 2, and 3 days after the induction of
performed with the Steel–Dwass test. ⁄P < 0.05 versus control or MSC-CM (exo).
d medium; MSC-CM (exo), mesenchymal-stem-cell-derived exosome-depleted
sion in DMEM.
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under a digital microscope BZ-9000 (Keyence, Japan).
2.10. Mouse model of cardiotoxin-induced muscle injury and local
injection of exosomes
This study was reviewed and approved by the Ethics Committee
for Experimental Animals of Hiroshima University, and all animals
were treated according to the guidelines of the Institutional Animal
Care and Use Committee. Eight-week-old male C57BL/6 mice (ﬁve
per group) were anesthetized with isoﬂurane. One hundred micro-
liter of 10 lM cardiotoxin (Sigma, USA) in PBS was injected into the
right side of the belly of the tibialis anterior muscle. PBS (50 ll) or
MSC-exosomes resuspended in PBS (50 ll) was injected into right
side of the belly of the tibialis anterior muscle 1, 3, and 5 days after
muscle injury.
2.11. Histological evaluation
Seven days after muscle injury, the tibialis anterior muscles of
each group were harvested and mounted in Tissue Freezing
Medium (Triangle Biomedical Sciences, USA), quickly frozen inFig. 3. Effects of MSC-exosomes on the angiogenic activity on HUVECs. (A) Migration
migrated cells are stained blue. Original magniﬁcation, 100. (B) In the tube formation as
8 days were measured. Original magniﬁcation, 200. Image fusion was performed. All dat
Steel–Dwass test. ⁄P < 0.05 versus control or MSC-CM (exo).liquid nitrogen, and stored at 80 C. The frozen muscles were cut
into 6 lmsections in the axial plane and air-dried. To evaluatemus-
cle regeneration, each sample was stained with hematoxylin and
eosin. Centronucleated myoﬁbers are recognized as regenerated
myoﬁbers. Conversely, preexisting myoﬁbers are identiﬁed by the
positions of their nuclei at the cell periphery. At200magniﬁcation
of the axial sections, the diameter and the total number of centronu-
cleatedmyoﬁbersweremeasured in four randomﬁelds. To evaluate
the ﬁbrotic area, each sample was stained with Masson trichrome.
The average areas of ﬁbrosis in the axial sections were determined
under a digital microscope (BZ-9000, Keyence).
2.12. Immunoﬂuorescence analysis to evaluate capillary density
Tissue sections were stained immediately with the following
primary antibodies: anti-dystrophin antibody (D8043; Sigma–
Aldrich) and anti-mouse CD31 antibody, a marker of endothelial
cells (MCA2388; AbD Serotec). The secondary antibodies were
Alexa-Fluor-549-conjugated anti-mouse IgG1 (for dystrophin)
and DyLight-488-conjugated anti-rat IgG (for CD31) (Jackson
ImmunoResearch). Four randomly selected areas in the axial sec-
tions were evaluated at 200 magniﬁcation.assay using HUVECs. The numbers of migrated cells were counted. Nuclei of the
say, the tube lengths of HUVECs that had been cocultured with human ﬁbroblasts for
a were calculated as means ± S.E. (n = 5). Statistical analysis was performed with the
Fig. 4. Improved tissue regeneration in mouse tibialis anterior muscle injury model following injection of MSC-exosomes. The effects of injection with mesenchymal-stem-
cell-derived exosomes were compared with the effects of phosphate-buffered saline injection in the cardiotoxin induced muscle injury model. (A) Representative histological
evaluation of regeneration, with hematoxylin and eosin staining. (B) Representative histological evaluation of ﬁbrosis with Masson trichrome staining. The ﬁbrotic area is
stained blue. (C) Representative histological evaluation of capillary density, with immunoﬂuorescent staining for CD31. Vascular endothelial cells are stained green. Original
magniﬁcation, 200. All data were calculated as means ± S.E. (n = 5). Statistical analysis was performed with the Mann–Whitney test. ⁄P < 0.05 versus control.
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The insulin-like growth factor 1 (IGF-1) levels in MSC-CM,
MSC-exosomes, and MSC-CM (exo) were measured with an
enzyme-linked immunosorbent assay (ELISA) using a Quantikine
Human IGF-1 ELISA (R&D Systems USA). Vascular endothelial
growth factor (VEGF), interleukin 6 (IL-6), ﬁbroblast growth
factor 2 (FGF2), granulocyte colony-stimulating factor (GCSF),
and platelet-derived growth factor-BB (PDGF-BB) levels in the
MSC-CM, MSC-exosomes, and MSC-CM (exo) were quantiﬁed
using the Bio-Plex Multiplex suspension assay system (Bio-Rad
Laboratories).
2.14. Nanostring nCounter miRNA analysis
MSC-exosomes were isolated from the total conditioned med-
ium (15 ml) on four independent MSCs seeded at 2.5  106 cells/
150  25 mm plate. SFB-derived exosomes (SFB-exosomes) were
also isolated under the same conditions as MSC-exosomes. The
small RNAs were puriﬁed from the MSC, MSC-exosomes, MSC-
CM (exo), and SFB-exosomes using the mirVana miRNA
Isolation Kit (Life Technologies). Puriﬁed small RNAs were enriched
using evaporator. The concentrations and quality of the small RNAs
from the same volumes of culture medium for the same numbers
of cells were determined with the BioAnalyzer 2100 (Agilent
Technologies, USA), and at least 5 ng of small RNA was used as
the input for the nCounter Human miRNA Expression Assay Kit(NanoString Technologies, USA). The miRNA expression proﬁles
were analyzed according to manufacturer’s instructions.
2.15. Transfection
C2C12 cells or HUVECs were transfected with miR-494 using
Lipofectamine RNAiMax Reagent (Invitrogen) using 10 or 50 nM
of miR-494 or control (siRNA negative control; siNega #1,
Ambion, USA). The sequences of the double-stranded miR-494
were: (sense) 50-AGGUUGUCCGUGUUGUCUUCUC-30 and (anti-
sense) 50-UGAAACAUACACGGGAAACCUC-30 (Hokkaido System
Sciences, Japan). C2C12 cells were induced to undergo myogenic
differentiation 24 h after transfection. The HUVECs were harvested
and used for migration assays.
2.16. Statistical analysis
The results are expressed as means ± S.E. The data were
analyzed with the Steel–Dwass test or the Mann–Whitney test.
P values <0.05 were considered to be statistically signiﬁcant.
3. Results and discussion
3.1. Exosomes from MSCs
The exosome markers CD9, CD81, and ﬂotillin-1 in
immunoblotting were present in the pellets (MSC-exosomes) after
Fig. 5. Cytokines, growth factors in MSC-exosomes. The concentrations of the muscle-repair-related cytokines in exosomes were measured in MSC-CM, MSC-exosomes, and
MSC-CM (exo) using ELISAs or Bio-Plex assays. Abbreviations: N.D., not detected. N = 4 independent hMSC.
Table 1
Top-20 microRNAs.
miRNAsa in MSC-
exosomesb
miRNAs in MSCc miRNAs in MSC-CM
(exo)d
1 hsa-miR-21-5p hsa-miR-125b-5p hsa-miR-4454
2 hsa-miR-4454 hsa-let-7a-5p hsa-miR-125b-5p
3 hsa-miR-378e hsa-miR-21-5p hsa-let-7a-5p
4 hsa-miR-125b-5p hsa-let-7b-5p hsa-miR-21-5p
5 hsa-miR-495 hsa-miR-4454 hsa-miR-720
6 hsa-miR-1183 hsa-miR-29b-3p hsa-miR-4286
7 hsa-miR-598 hsa-miR-23a-3p hsa-miR-4488
8 hsa-miR-25-3p hsa-miR-199a-
3p + 199b-3p
hsa-let-7b-5p
9 hsa-miR-570-3p hsa-let-7i-5p hsa-miR-23a-3p
10 hsa-miR-720 hsa-miR-100-5p hsa-miR-199a-
3p + 199b-3p
11 hsa-miR-302d-3p hsa-miR-29a-3p hsa-miR-378e
12 hsa-miR-23a-3p hsa-let-7g-5p hsa-miR-145-5p
13 hsa-miR-548al hsa-miR-221-3p hsa-miR-4516
14 hsa-miR-579 hsa-miR-15a-5p hsa-miR-100-5p
15 hsa-miR-630 hsa-miR-143-3p hsa-let-7g-5p
16 hsa-miR-888-5p hsa-miR-16-5p hsa-miR-4454
17 hsa-miR-155-5p hsa-miR-22-3p hsa-miR-221-3p
18 hsa-miR-761 hsa-miR-145-5p hsa-let-7i-5p
19 hsa-miR-375 hsa-miR-27b-3p hsa-miR-1260a
20 hsa-miR-548aa hsa-miR-125a-5p hsa-miR-630
Listed are the top 20 miRNAs according to their expression levels in MSC-exosomes,
MSC, and MSC-CM (exo) according to the NanoString miRNA proﬁle (n = 4).
miRNAs in bold font were expressed at highly levels in MSC.
a miRNAs = microRNAs.
b MSC-exosomes = mesenchymal-stem-cell-derived exosomes.
c MSC = mesenchymal stem cell.
d MSC-CM (exo) = mesenchymal-stem-cell-derived exosome-depleted condi-
tioned medium.
Table 2
MicroRNA ratio of MSC-exosomes to SFB-exosomes.
miRNAa Ratio MSC-exob:SFB-exoc MSC-exo SFB-exo
miR-494 8.34 1313.03 157.5
*miR-601 4.52 483.09 106.88
*miR-548b-5p 3.88 54.5 14.06
*miR-1246 3.78 2923.34 773.46
*miR-607 3.40 66.89 19.69
*miR-1915-3p 3.29 175.9 30.16
*miR-187-3p 3.27 193.24 59.06
*miR-4488 3.05 822.5 270.01
miR-378d 2.85 104.05 36.56
miR-188-3p 2.81 213.06 75.94
*miR-548aa 2.80 1322.94 472.51
*miR-1469 2.77 54.5 19.69
*miR-552 2.75 131.3 47.81
*miR-520d-3p 2.64 104.05 39.38
miR-1306-3p 2.64 74.32 28.13
miR-214-3p 2.58 109.01 42.19
*miR-3154 2.51 91.66 36.56
*miR-1226-3p 2.50 126.35 50.63
a miRNAs = microRNAs.
b MSC-exo = mesenchymal-stem-cell-derived exosomes.
c SFB-exo = synovial-ﬁbroblast-derived exosomes.
* These miRNAs are not identiﬁed in mice. Differentially contained microRNAs (at
least 2.5-fold difference) are shown as the ratio of MSC-exo to SFB-exo. Values for
microRNAs in MSC-exo and SFB-exo are miRNAs count (miRNAs levels).
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natants (MSC-CM (exo)) after ultracentrifugation (Fig. 1A). The
size distribution of the particles in the pellets after ultracen-
trifugation was measured with the qNano system. The numbers
and sizes of particles derived from the four different MSCs were
very similar. The major peak in particle size was at 65–75 nm
and the overall size distribution ranged between 60 and 200 nm
(Fig. 1B). These results indicate that exosomes were isolated with
this ultracentrifugation protocol.3.2. MSC-CM and MSC-exosomes promote myogenesis and
angiogenesis in vitro
The effects of MSC-conditioned medium (MSC-CM), MSC-exo-
some suspension in DMEM (MSC-exosome), and exosome-de-
pleted MSC-conditioned medium (MSC-CM (exo)) on myoblast
proliferation and differentiation were analyzed in C2C12 cells.
MSC-CM and MSC-exosomes signiﬁcantly increased the total
nuclear number and the fusion indices of the C2C12 cells compared
with those of the control group and the MSC-CM (exo) group
(Fig. 2A and B). The expression of myogenic marker genes, such
as Myog, increased for a period of 3 days during differentiation in
all groups. The expression of Myod1 and Myog was signiﬁcantly
higher in the MSC-CM and MSC-exosome groups than in the con-
trol group (Fig. 2C). In contrast, the expression of Myod1 and
Myog in the MSC-CM (exo) group was not signiﬁcantly different
from that in the control group on all days (Fig. 2C). These results
Y. Nakamura et al. / FEBS Letters 589 (2015) 1257–1265 1263suggest that MSC-CM and MSC-exosomes including exosomes pro-
mote both the proliferation and differentiation of C2C12 cells. To
analyze the effects of MSC-CM, MSC-exosomes, and MSC-CM
(exo) on angiogenic activity in vitro, migration and tube forma-
tion assays were performed. In migration assay using HUVECs,
the numbers of migrated cells increased signiﬁcantly after treat-
ment with MSC-CM, MSC-exosomes, or MSC-CM (exo) compared
with the control DMEM (Fig. 3A). The tube length in the HUVECs
was signiﬁcantly greater after 8 days incubation with MSC-CM or
MSC-exosomes compared with control DMEM (Fig. 3B). Our
in vitro studies showed that the MSC-exosomes signiﬁcantly pro-
moted myogenesis and angiogenesis.
3.3. MSC-exosomes promote muscle regeneration in a muscle injury
model
To evaluate the effects of MSC-exosomes on muscle regenera-
tion in vivo, we used the cardiotoxin muscle injury model in mice.
Three days after muscle injury, the myoﬁbers showed complete
necrosis in both the control group and MSC-exosome-injected
group. Seven days after muscle injury, centronucleated myoﬁbersFig. 6. Effects of miR-494 on the differentiation of C2C12 cells, the migration activity of H
blue. Original magniﬁcation, 200. (B) Total numbers of nuclei indicate myoblast prolife
performed with HUVECs transfected with miR-494 or siNega. Nuclei of migrated cells
Statistical analysis was performed with the Steel–Dwass test. ⁄P < 0.05 versus siNega. Ab
RNA, negative silencing control.appeared in both the control group and the MSC-exosome group.
The diameters and numbers of centronucleated myoﬁbers were
signiﬁcantly higher in the MSC-exosome-injected group after
7 days than in the control group (Fig. 4A). The ﬁbrotic area was sig-
niﬁcantly smaller in the MSC-exosome group than in the control
group (Fig. 4B). The capillary density was signiﬁcantly greater in
the MSC-exosome group than in the control group (Fig. 4C). Our
in vivo analysis in a mouse model of muscle injury showed that
the injection of MSC-exosomes accelerated histological muscular
regeneration, with enhanced angiogenesis and reduced ﬁbrosis.
Although our in vivo data do not clarify whether the injected
MSC-exosomes were incorporated into speciﬁc cells in the muscle
tissue, our in vitro and in vivo data support the hypothesis that
MSC-derived exosomes promote skeletal muscle repair by
accelerating myogenesis and angiogenesis.
3.4. Cytokines, growth factors, and miRNAs in MSC-exosomes
We examined cytokines (102 proteins) in MSC-exosomes, MSC-
CM and MSC-CM (exo) using Cytokine Antibody Array (data not
shown). Then, the levels of picked-up protein were quantiﬁedUVECs. (A) Myotubes are stained for myosin heavy chain (red) and nuclei are stained
ration. Fusion index reﬂects differentiation in C2C12 cells. (C) Migration assay was
are stained blue. Original magniﬁcation, 100. All data are means ± S.E. (n = 5).
breviations: miR-494, microRNA-494; n.s., not signiﬁcant; siNega, small interfering
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MSC-CM and MSC-CM (exo) included signiﬁcant amounts of
VEGF and IL-6 which are known to be associated with skeletal
muscle [23,24]. However, MSC-exosomes included signiﬁcantly
lower VEGF and IL-6 levels than MSC-CM or MSC-CM (exo). The
levels of FGF-2, GCSF, and PDGF-BB which are muscle-repair-
related cytokines were no difference in all groups. IGF-1 was not
detectable in any sample (Fig. 5). These results suggest that the
paracrine effects of MSCs are not only attributable to cytokines
and growth factors, but also to other factors, such as exosomes.
Therefore, MSC-derived exosomes may function as a novel reg-
ulatory factor that contributes to the regeneration of skeletal mus-
cle. This prompted us to examine miRNA in MSC-exosomes, MSC
and MSC-CM (exo) using a NanoString miRNA analysis. Among
the top 20 miRNAs, miRNAs in MSC-CM (exo) almost coincided
with highly expressed miRNAs in MSC but not in the MSC-
exosomes (Table 1). miR-21, an antiapoptotic miRNA [25], was
detected at the highest concentrations in MSC-exosomes. Many
miRNAs including miR-21 were present in both MSC-exosomes
and MSC-CM (exo). However, we reported that exosome-formed
miRNAs may be more functional extracellular miRNA than non-
exosome-formed miRNAs [26]. We observed that miRNAs related
to tissue regeneration, such as antiapoptotic and antioxidant
miRNAs, were present in the MSC-exosomes. In fact, the antiapop-
totic and antioxidant effects of MSC-conditioned medium have
been reported [12–14]. We also detected other myogenic miRNAs
in exosomes, including miR-1, miR-133, and miR-206. The local
injection of these miRNAs accelerated muscle regeneration in a
rat model of skeletal muscle injury [27]. The contents of exosomes,
including proteins, miRNAs, and mRNAs, vary according to the cell
type that secretes them [9,10]. To focus on speciﬁc miRNAs in the
MSC-exosomes, furthermore, we compared SFB-exosomes with
MSC-exosomes (Table 2). Several miRNAs were identiﬁed only in
exosomes and miRNAs such as miR-494 was contained abundantly
in MSC-exosomes compared with SFB-exosomes. The injection of
MSC-derived exosomes and the cardiac-speciﬁc overexpression of
miR-494 have been reported to protect against ischemia/reperfu-
sion-induced cardiac injury [15,16,28]. These reports suggest the
miR-494 in MSC-exosomes is important in tissue repair.
3.5. miR-494 enhance myogenesis and migration activity
Recently, Yamamoto et al. showed that miR-494 was decreased
in C2C12 during myogenesis, and regulated mitochondorial bio-
genesis via Mitochondrial transcription factor A (mtTFA) and
Forkhead box j3 (FOXj3) [29]. To evaluate the effects of miR-494
on myogenesis and migration activities, C2C12 cells or HUVECs
were transfected with miR-494. The numbers of nuclei in C2C12
cells transfected with miR-494 did not differ signiﬁcantly from
those in cells transfected with siNega. The fusion indices of
C2C12 cells transfected with miR-494 were signiﬁcantly higher
than those of cells transfected with siNega (Fig. 6A and B). The
migration activity of HUVECs transfected with miR-494 was sig-
niﬁcantly higher than that of cells transfected with siNega
(Fig. 6C). Although the introduction of a single high-dose miRNA
into cells may not reﬂect the function of that miRNA in exosomes,
these results have shown that miR-494 participates in C2C12
myogenesis and HUVEC migration. Many studies have not
addressed the direct effects of mediators in exosomes, such as
miRNAs. The study of neurological diseases and injury has demon-
strated that the transfer of miRNAs to neural cells via exosomes
from MSCs contributes to neurite outgrowth [17]. Although the
physiological properties of exosomes are incompletely understood,
these reports support our ﬁnding that MSC-derived exosomes pro-
mote muscle regeneration at least in part via miRNAs (see Fig. 6).Exosomes including miRNAs from MSCs may explain the
mechanism of skeletal muscle regeneration during MSC trans-
plantation, in addition to their secretion of cytokines, chemokines,
or growth factors and may be a new therapeutic tool.
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